Atika Capital Management Boosts Stake in Guardant Health

Institutional investor increases position in cancer diagnostics company by nearly 50%

Mar. 12, 2026 at 7:05am

Got story updates? Submit your updates here. ›

Atika Capital Management LLC, an investment management firm, has increased its stake in Guardant Health, Inc. (NASDAQ:GH) by 49.1% during the third quarter of 2025. The fund now owns 133,000 shares of the company's stock, valued at $8.31 million.

Why it matters

Guardant Health is a leading provider of liquid biopsy tests for cancer detection and monitoring. The increase in Atika Capital's position suggests the firm sees strong growth potential in the company's technology and market opportunities.

The details

According to a 13F filing with the Securities and Exchange Commission, Atika Capital Management purchased an additional 43,800 shares of Guardant Health during the third quarter. This brings the firm's total ownership in the company to 0.11% of outstanding shares. Guardant Health's liquid biopsy tests use circulating tumor DNA to profile genomic alterations in cancer patients, providing clinicians with actionable data to guide treatment decisions.

  • Atika Capital Management increased its stake in Guardant Health during the third quarter of 2025.

The players

Atika Capital Management LLC

An investment management firm that has increased its stake in Guardant Health, Inc.

Guardant Health, Inc.

A precision oncology company specializing in blood-based cancer diagnostics.

Got photos? Submit your photos here. ›

The takeaway

Atika Capital's increased investment in Guardant Health underscores the growing importance of liquid biopsy technology in cancer care. As the company continues to innovate and expand its product offerings, it may attract further interest from institutional investors seeking exposure to this rapidly evolving field.